Needham & Company LLC reiterated their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a research report sent to investors on Monday, December 23rd, AnalystRatings.com reports. Needham & Company LLC currently has a $84.00 price objective on the stock.
Several other equities research analysts also recently issued reports on the company. ValuEngine raised Crispr Therapeutics from a sell rating to a hold rating in a research note on Friday, November 1st. Roth Capital increased their price objective on Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. BidaskClub downgraded Crispr Therapeutics from a strong-buy rating to a buy rating in a research note on Friday, December 13th. Oppenheimer increased their price objective on Crispr Therapeutics from $65.00 to $80.00 and gave the stock an outperform rating in a research note on Monday, November 25th. Finally, Canaccord Genuity increased their price objective on Crispr Therapeutics from $72.00 to $80.00 and gave the stock a positive rating in a research note on Wednesday, November 20th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $71.38.
Shares of CRSP stock opened at $60.91 on Monday. The stock has a 50-day simple moving average of $65.68 and a 200 day simple moving average of $50.89. Crispr Therapeutics has a fifty-two week low of $27.11 and a fifty-two week high of $74.00. The stock has a market capitalization of $3.41 billion, a P/E ratio of -17.70 and a beta of 3.31. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06.
Crispr Therapeutics (NASDAQ:CRSP) last announced its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The business had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. On average, sell-side analysts anticipate that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the completion of the transaction, the director now directly owns 7,500 shares in the company, valued at $390,000. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,118 shares of company stock worth $3,620,760. Insiders own 21.40% of the company’s stock.
A number of hedge funds have recently modified their holdings of CRSP. Nikko Asset Management Americas Inc. increased its position in Crispr Therapeutics by 48.4% in the 3rd quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after purchasing an additional 906,006 shares during the last quarter. Orbimed Advisors LLC acquired a new position in shares of Crispr Therapeutics during the 3rd quarter valued at about $21,167,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Crispr Therapeutics by 19.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after acquiring an additional 121,176 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Crispr Therapeutics by 23.9% during the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after acquiring an additional 116,540 shares during the last quarter. Finally, Balyasny Asset Management LLC acquired a new position in shares of Crispr Therapeutics during the 2nd quarter valued at about $5,165,000. 49.82% of the stock is currently owned by institutional investors.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: What does cost of debt say about a company’s financial health?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.